Ovulation Induction

2
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Gedeon Richter
Gedeon RichterHungary - Budapest
1 program
1
Myo-inositolPhase 41 trial
Active Trials
NCT04306692Terminated12Est. Jan 2022
M&
Merck & Co.RAHWAY, NJ
1 program
1
Recombinant FSHPhase 42 trials
Active Trials
NCT06732843Recruiting10Est. Jul 2027
NCT01081626Completed310Est. Mar 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Gedeon RichterMyo-inositol
Merck & Co.Recombinant FSH
Merck & Co.Recombinant FSH

Clinical Trials (3)

Total enrollment: 332 patients across 3 trials

Myo-inositol Versus Clomiphene Citrate in PCOS

Start: Jul 2020Est. completion: Jan 202212 patients
Phase 4Terminated
NCT01081626Merck & Co.Recombinant FSH

Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction

Start: Mar 2009Est. completion: Mar 2011310 patients
Phase 4Completed
NCT06732843Merck & Co.Recombinant FSH

Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?

Start: Jul 2025Est. completion: Jul 202710 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 332 patients
2 companies competing in this space